After chest tube was placed to treat the pneumothorax, the patient's breathing and chest pains was resolved.Pneumothorax is the most common device related serious adverse event that is associated with the spiration valve system.In the emprove study, the incidence of serious pneumothorax was 14.2%, with over 75% of the serious pneumothorax events occurring within the first 3 days post-procedure.Early-onset pneumothorax in the treatment group likely resulted from lung conformation changes due to acute reduction in lung volume by valve therapy, triggering rapid expansion of the ipsilateral non-targeted lobe leading to a pneumothorax.(criner et al.Improving lung function in severe heterogenous emphysema with the spiration® valve system (emprove): a multicenter, open-label, randomized, controlled trial.Am j respir crit care med.2019 jul 31.Doi: 10.1164/rccm.201902-0383oc.[epub ahead of print]).However, it should be noted that pneumothorax events are also recognized as an indicator of successful target lobe occlusion and when managed according to published expert guidelines (valipour et al.Expert statement: pneumothorax associated with endoscopic valve therapy for emphysema ¿ potential mechanisms, treatment algorithm and case examples.Respiration 2014; 8: 513-521), subjects with pneumothorax events experienced clinical benefits similar to that in subjects without pneumothorax events (criner et al.Ajrccm 2019 jul 31.Doi:10.1164/rccm.201902-0383oc.[epub ahead of print].The reported event aligns with the experience in the emprove clinical trial and is an expected adverse event associated with the spiration valve system.
|